SCHEMBL29777969

SCHEMBL29777969

CC(C)=CCC[C@@]1(C)C=Cc2c(cc(O)c(C(=O)O)c2C)O1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.66
APP P05067 2/20 0.66
SLC6A2 P23975 2/20 0.63
HRH1 P35367 1/20 0.63
OPRM1 P35372 1/20 0.63
TRPA1 O75762 1/20 0.56
LDHA P00338 1/20 0.56
CNR1 P21554 1/20 0.56
SLC6A4 P31645 1/20 0.56
CNR2 P34972 1/20 0.56
SLC6A3 Q01959 1/20 0.56
TRPM8 Q7Z2W7 1/20 0.56
TRPV1 Q8NER1 1/20 0.56
TRPV3 Q8NET8 1/20 0.56
TRPV4 Q9HBA0 1/20 0.56
TRPV2 Q9Y5S1 1/20 0.56
CTSK P43235 1/20 0.50
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21426166 0.84 PTPN1 (0.88) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL29467209 0.84 PTPN1 (0.88) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL23987190 0.83 APP (0.63) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL25560683 0.81 SLC6A2 (0.83) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL13214114 0.80 SLC6A2 (0.87) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL23363576 0.80 SLC6A2 (0.87) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL26487390 0.80 SLC6A2 (0.87) PTPN1APPSLC6A2HRH1OPRM1
SCHEMBL30125514 0.79 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1
Daurichromenic Acid SCHEMBL29424248 0.79 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1
Daurichromenic Acid SCHEMBL11218399 0.79 PTPN1 (1.00) PTPN1APPSLC6A2HRH1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220362320-A1 METHODS FOR PREPARING EXTRACTS FROM PLANTS AND FUNGI CANNA STREAM SOLUTIONS LTD. (CA) 2022-11-17 US claimed
US-20220273585-A1 Composition comprising at least one natural or synthetic non-euphoric cannabinoid and its method of manufacture TILMAN (BE) 2022-09-01 US claimed
EP-4049654-A1 COMPOSITION COMPRISING AT LEAST ONE NATURAL OR SYNTHETIC CANNABINOID WITHOUT EUPHORIC EFFECT AND MANUFACTURING METHOD THEREOF Eleonor (BE) 2022-08-31 EP claimed
US-20250000806-A1 Dry Powdered Formulations PINATA HOLDINGS INC. 2025-01-02 US disclosed
US-20240358650-A1 INHALABLE HORMONE RECEPTOR AGONIST FORMULATIONS PINATA HOLDINGS INC. 2024-10-31 US disclosed
US-20240358649-A1 INHALABLE HORMONE RECEPTOR AGONIST FORMULATIONS PINATA HOLDINGS INC. 2024-10-31 US disclosed
US-20240299297-A1 STABLE EMULSIONS AND METHODS HEMP HUNTER LABS INC (US) 2024-09-12 US disclosed
US-20240041782-A1 Oral Capsule Cannabinoid Formulations PINATA HOLDINGS INC. 2024-02-08 US disclosed
EP-4284321-A1 STABLE EMULSIONS AND METHODS Hemp Hunter Labs Inc. (US) 2023-12-06 EP disclosed
US-20230381206-A1 DRINK CONTAINING A FROZEN CANNABIS PRODUCT AND METHOD OF MAKING HOT ICE LLC (US) 2023-11-30 US disclosed
WO-2023230475-A1 DRINK CONTAINING A FROZEN CANNABIS PRODUCT AND METHOD OF MAKING Hot Ice, LLC (US) 2023-11-30 WO disclosed
US-20230293555-A1 COMPOSITIONS COMPRISING CANNABIDIOL AND FLAVANONES YUZU LV LLC 2023-09-21 US disclosed
WO-2023006699-A1 CELLS AND METHOD FOR PRODUCING ISOPRENOID MOLECULES WITH CANONICAL AND NON-CANONICAL STRUCTURES Københavns Universitet (DK) 2023-02-02 WO disclosed
US-20220362320-A1 METHODS FOR PREPARING EXTRACTS FROM PLANTS AND FUNGI CANNA STREAM SOLUTIONS LTD. (CA) 2022-11-17 US disclosed
US-20220273585-A1 Composition comprising at least one natural or synthetic non-euphoric cannabinoid and its method of manufacture TILMAN (BE) 2022-09-01 US disclosed
EP-4049654-A1 COMPOSITION COMPRISING AT LEAST ONE NATURAL OR SYNTHETIC CANNABINOID WITHOUT EUPHORIC EFFECT AND MANUFACTURING METHOD THEREOF Eleonor (BE) 2022-08-31 EP disclosed
WO-2022165006-A1 STABLE EMULSIONS AND METHODS HEMP HUNTER LABS INC. (US) 2022-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041782-A1 Oral Capsule Cannabinoid Formulations CNR2, CNR1, FAAH PTPN1 4318/4885APP 1601/4885SLC6A2 1372/4885
US-20220273585-A1 Composition comprising at least one natural or synthetic non-euphoric cannabinoid and its method of manufacture CNR2, CNR1, FAAH PTPN1 2037/4885APP 681/4885SLC6A2 231/4885
US-20250000806-A1 Dry Powdered Formulations LIPA, ADCYAP1R1, PCSK9 PTPN1 4023/4885APP 271/4885SLC6A2 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.